Protocol Library

Researched as an NNMT inhibitor in metabolic studies.

Vial

50 mg

Dose

50–150 mg daily (research literature, oral)

Freq

Once daily (research example)

Cycle

4–8 weeks (research example)

Commonly researched for cognitive focus, attention research, neuroprotection research and BDNF-related signaling discussion.

Vial

5 mg

Dose

Research literature commonly cites 200–600 mcg per research day intranasal-equivalent in published protocols.

Freq

Once or twice daily in research scheduling examples.

Cycle

10–20 days per research cycle.

Commonly researched for adipose-tissue biology, body-composition models and obesity research in laboratory settings.

Vial

10 mg

Dose

Published preclinical research has used very low body-weight-scaled amounts; specific human protocols are not established and are not provided here.

Freq

Short research courses described in preclinical literature.

Cycle

Short cycles in preclinical models only.

Used in research contexts to study AMPK pathway activation, mitochondrial biogenesis and substrate utilization.

Vial

50 mg lyophilized vial

Dose

Research literature ranges vary widely; educational example only.

Freq

Protocol-dependent in research.

Cycle

Short cycles in published research designs.

Researched in fat metabolism contexts.

Vial

5 mg

Dose

250–500 mcg daily (research literature)

Freq

Once daily (research example)

Cycle

8–12 weeks (research example)

Studied in research contexts for incretin pathway activity and metabolic markers.

Vial

5 mg lyophilized vial

Dose

Educational research dose example only.

Freq

Weekly in research designs.

Cycle

Multi-week educational examples.

Commonly researched for tendon, ligament, gut lining and wound repair contexts.

Vial

5 mg

Dose

200–500 mcg daily (research literature)

Freq

1–2x daily (research example)

Cycle

4–8 weeks (research example)

Researched for amylin receptor activity, gastric emptying and satiety endpoints.

Vial

5 mg lyophilized vial

Dose

Commonly discussed research range: 0.3–2.4 mg weekly.

Freq

Weekly.

Cycle

12–20 week educational example.

Commonly researched for cartilage, connective-tissue and joint research models.

Vial

20 mg

Dose

Research literature commonly references 100–200 mcg per research day.

Freq

Once daily in research scheduling examples.

Cycle

10–20 days per research cycle, often repeated 2–3 times per year in published bioregulator protocols.

Studied for its role in neurotrophic signaling, cognitive research and post-ischemic neurological research models.

Vial

5 ml ampoule

Dose

Published clinical research commonly cites 5–30 ml per research day intravenous-equivalent ranges.

Freq

Daily research dosing across multi-week courses in published studies.

Cycle

Common research courses: 10–30 days.

Commonly researched for respiratory tissue homeostasis, bronchial epithelium research and pulmonary bioregulator contexts.

Vial

20 mg

Dose

Research literature commonly references 100–200 mcg per research day.

Freq

Once daily in research scheduling examples.

Cycle

10–20 days per research cycle.

Researched in growth hormone pulse research, often paired with GHRPs.

Vial

2 mg

Dose

100 mcg per use (research literature)

Freq

1–3x daily (research example)

Cycle

8–12 weeks (research example)

Researched in studies of sustained GH/IGF-1 elevation.

Vial

2 mg

Dose

1–2 mg weekly (research literature)

Freq

1–2x weekly (research example)

Cycle

8–12 weeks (research example)

Commonly researched for cognitive, neuroprotection and nervous-system bioregulator contexts.

Vial

20 mg

Dose

Research literature commonly references 100–200 mcg per research day.

Freq

Once daily in research scheduling examples.

Cycle

10–20 days per research cycle.

Researched in sleep architecture studies.

Vial

5 mg

Dose

100–300 mcg before sleep (research literature)

Freq

Pre-sleep (research example)

Cycle

2–4 weeks (research example)

Researched in pineal and telomerase contexts.

Vial

10 mg

Dose

5–10 mg daily (research literature)

Freq

Once daily (research example)

Cycle

10–20 days (research example)

Investigated for disruption of FOXO4–p53 interaction in senescent cells.

Vial

5 mg lyophilized vial

Dose

Educational research dose example only; preclinical literature.

Freq

Pulsed protocols in research designs.

Cycle

Short pulsed cycles.

Researched in dermal repair, hair follicle, and anti-aging contexts.

Vial

50 mg

Dose

1–2 mg per use (research literature)

Freq

Topical or subq (research example)

Cycle

4–8 weeks (research example)

Investigated for pulsatile growth hormone release via ghrelin receptor agonism.

Vial

5 mg lyophilized vial

Dose

Commonly discussed research range: 100–300 mcg per administration.

Freq

2–3x daily in research designs.

Cycle

8–12 week educational example.

Investigated for GH pulsatility and appetite signaling via ghrelin receptor agonism.

Vial

5 mg lyophilized vial

Dose

Commonly discussed research range: 100–300 mcg per administration.

Freq

2–3x daily in research designs.

Cycle

8–12 week educational example.

Studied as a combined research peptide profile for repair-related endpoints.

Vial

Blend vial (varies by source)

Dose

Educational research dose example only.

Freq

Daily or alternating-day research designs.

Cycle

4–8 week educational example.

Researched as a master antioxidant in oxidative stress contexts.

Vial

600 mg

Dose

200–600 mg per use (research literature)

Freq

1–3x weekly (research example)

Cycle

4–8 weeks (research example)

Studied for its role in the HPG axis, LH/FSH signaling research and reproductive endocrinology research models.

Vial

10 mg

Dose

Published research literature describes microgram-range pulses (e.g. 25–200 mcg).

Freq

Pulsatile schedules described in research literature — frequently every few days.

Cycle

Highly protocol-dependent in published material.

Studied for its role in LH receptor signaling research, gonadal function research models and reproductive endocrinology research.

Vial

5000 IU

Dose

Published research literature commonly references 250–1500 IU range research scheduling.

Freq

Multiple times per week in published research scheduling examples.

Cycle

Multi-week research courses in published examples.

Researched in lipolysis and adipose tissue contexts.

Vial

5 mg

Dose

250–500 mcg daily (research literature)

Freq

1–2x daily (research example)

Cycle

8–12 weeks (research example)

Investigated for local IGF-1 receptor activity with reduced IGFBP binding.

Vial

1 mg lyophilized vial

Dose

Commonly discussed research range: 50–100 mcg per site.

Freq

Site-specific in research designs.

Cycle

4 week educational example.

Studied for its role in IGF-1 pathway research, cellular growth signaling and muscle-research models.

Vial

1 mg

Dose

Published research literature commonly cites 20–50 mcg per research day in cellular and animal study ranges.

Freq

Once daily in research scheduling examples.

Cycle

Short research cycles (commonly 4–6 weeks).

Researched as a selective ghrelin receptor agonist in GH studies.

Vial

5 mg

Dose

100–300 mcg per use (research literature)

Freq

1–3x daily (research example)

Cycle

8–12 weeks (research example)

Studied for its role in GnRH stimulation research, reproductive-axis research and endocrine signaling research.

Vial

1 mg

Dose

Research literature has used a wide micro- to milligram range depending on study model.

Freq

Highly protocol-dependent in published material.

Cycle

Short research courses in published study models.

Researched in mucosal and inflammatory pathway studies.

Vial

10 mg

Dose

200–500 mcg daily (research literature)

Freq

1–2x daily (research example)

Cycle

2–4 weeks (research example)

Studied for its role in fatty-acid transport, mitochondrial metabolism, endurance research and metabolic energy research.

Vial

200 mg/ml ampoule

Dose

Published research literature references a broad range; commonly cited examples include 500–2000 mg per research day.

Freq

Often daily in research scheduling examples.

Cycle

Continuous research periods are common.

Studied for hepatic lipid metabolism research contexts.

Vial

Multi-dose vial (varies)

Dose

Educational research range varies by formulation.

Freq

Weekly research administration example.

Cycle

4–12 week educational example.

Investigated in research literature for chromatin decondensation and lymphocyte activity.

Vial

20 mg lyophilized vial

Dose

Educational research dose example only.

Freq

Daily in short research cycles.

Cycle

10–20 day educational example.

Investigated for combined GLP-1 and glucagon receptor activity on metabolic endpoints.

Vial

5 mg lyophilized vial

Dose

Commonly discussed research range: 1.5–9 mg weekly.

Freq

Weekly.

Cycle

12–24 week educational example.

Researched in melanocortin pathway studies.

Vial

10 mg

Dose

250–500 mcg per use (research literature)

Freq

Variable (research example)

Cycle

4 weeks (research example)

Researched in mitochondrial and metabolic regulation contexts.

Vial

10 mg

Dose

5–10 mg weekly (research literature)

Freq

2–3x weekly (research example)

Cycle

4–8 weeks (research example)

Researched in NAD+ metabolism and cellular energy contexts.

Vial

500 mg

Dose

100–500 mg per use (research literature)

Freq

1–3x weekly (research example)

Cycle

4–8 weeks (research example)

Studied for its role in neuropeptide signaling research, stress research, social behavior research and mood-related research.

Vial

2 mg

Dose

Research literature references microgram intranasal-equivalent ranges (e.g. 20–40 IU per research session in intranasal protocols).

Freq

As-needed scheduling in many study models.

Cycle

Short research periods.

Investigated for myogenic precursor activation via MGF/IGF-1Ec splice variant pathway.

Vial

2 mg lyophilized vial

Dose

Commonly discussed research range: 200–400 mcg per administration.

Freq

2–3x weekly in research designs.

Cycle

4–6 week educational example.

Investigated for neuroprotective signaling in preclinical research literature.

Vial

20 mg lyophilized vial

Dose

Educational research dose example only.

Freq

Daily in short research cycles.

Cycle

10–20 day educational example.

Investigated for selective membrane interaction with HDM-2-expressing cells in preclinical research.

Vial

10 mg lyophilized vial

Dose

Educational research dose example only; preclinical literature.

Freq

Protocol-dependent.

Cycle

Short pulsed research cycles.

Investigated in Khavinson-school research for organ-specific peptide signaling.

Vial

20 mg lyophilized vial

Dose

Educational research dose example only.

Freq

Daily in short research cycles.

Cycle

10–20 day educational example.

Researched in MC4R activation contexts.

Vial

10 mg

Dose

0.5–2 mg per use (research literature)

Freq

As-needed (research example)

Cycle

Short cycles (research example)

Researched as a triple receptor agonist for metabolic and bodyweight studies.

Vial

10 mg

Dose

1 mg – 12 mg weekly (research literature)

Freq

Once weekly (research example)

Cycle

12+ weeks (research example)

Researched in GABAergic and anxiolytic contexts.

Vial

10 mg

Dose

250–500 mcg daily (research literature, intranasal common)

Freq

1–2x daily (research example)

Cycle

2–4 weeks (research example)

Commonly researched in studies of appetite regulation, satiety, and glucose metabolism.

Vial

5 mg

Dose

0.25 mg – 2.4 mg weekly (research literature)

Freq

Once weekly (research example)

Cycle

12+ weeks (research example)

Researched in BDNF and cognitive performance contexts.

Vial

30 mg

Dose

200–600 mcg daily (research literature, intranasal common)

Freq

1–2x daily (research example)

Cycle

2–4 weeks (research example)

Researched as a GHRH analog in pituitary GH release studies.

Vial

5 mg

Dose

100–300 mcg per use (research literature)

Freq

Nightly (research example)

Cycle

8–12 weeks (research example)

Investigated for SNARE complex modulation in topical cosmetic research.

Vial

Topical research solution

Dose

Educational research concentration example only.

Freq

Topical research application example.

Cycle

Multi-week educational example.

Researched in mitochondrial cardiolipin and energy production contexts.

Vial

10 mg

Dose

1–5 mg daily (research literature)

Freq

Once daily (research example)

Cycle

4–8 weeks (research example)

Investigated for combined incretin and glucagon receptor activity.

Vial

5 mg lyophilized vial

Dose

Commonly discussed research range: 0.3–4.8 mg weekly.

Freq

Weekly.

Cycle

12–24 week educational example.

Researched in soft tissue, muscle, and vascular repair contexts.

Vial

5 mg

Dose

2–5 mg weekly (research literature)

Freq

1–2x weekly (research example)

Cycle

4–6 weeks (research example)

Researched in studies of visceral adipose tissue.

Vial

5 mg

Dose

1–2 mg daily (research literature)

Freq

Once daily (research example)

Cycle

12+ weeks (research example)

Investigated for thymic-related signaling in Khavinson-school research literature.

Vial

20 mg lyophilized vial

Dose

Educational research dose example only.

Freq

Daily in short research cycles.

Cycle

10–20 day educational example.

Researched in T-cell and immune support contexts.

Vial

5 mg

Dose

1.6 mg twice weekly (research literature)

Freq

2x weekly (research example)

Cycle

4–8 weeks (research example)

Studied for dual GIP/GLP-1 receptor activity in metabolic research contexts.

Vial

10 mg

Dose

2.5 mg – 15 mg weekly (research literature)

Freq

Once weekly (research example)

Cycle

12+ weeks (research example)

Investigated for vascular endothelial signaling in research literature.

Vial

20 mg lyophilized vial

Dose

Educational research dose example only.

Freq

Daily in short research cycles.

Cycle

10–20 day educational example.

Investigated for immunomodulatory and chromatin-related signaling research.

Vial

20 mg lyophilized vial

Dose

Educational research dose example only.

Freq

Daily in short research cycles.

Cycle

10–20 day educational example.